MAM. Amin Arnaout

M. Amin Arnaout

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


M. Amin Arnaout has a total of 146 co-authors. Here are the top co-authors by number of shared publications:

  • Johannes van Agthoven

    Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    13 shared publications
  • Jian-Ping Xiong

    Leukocyte Biology and Inflammation Laboratory, Division of Nephrology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA

    11 shared publications
  • Brian D. Adair

    Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    7 shared publications
  • José L. Alonso

    Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, USA

    5 shared publications
  • Brian Adair

    Division of Nephrology, Department of Medicine, Harvard Medical School, USA

    3 shared publications
  • Hyun Sook Ahn

    Division of Hematology, The Children’s Hospital of Philadelphia, Philadelphia, USA

    3 shared publications

Latest Publications

  • Testican-2 Interaction with the Extracellular Matrix and Podocyte Protection

    by Donghai Wen, Qian Zhang, Johannes van Agthoven, Astrid Weins, Ivy A. Rosales, Wen Zhou, Taesoo Kim, Xavier Vela Parada, Robert B. Colvin, Martin R. Pollak, et al.

    Key Points: Testican-2 reduced adriamycin-induced podocyte injury in vitro and in vivo . Testican-2 interacted with vitronectin and reduced vitronectin-mediated integrin α V β 3 activation in vitro . Exogenous testican-2 circulated to the kidney, bound vitronectin, and conferred podocyte protection, even when endogenous testican-2 was absent. Background: Testican-2 is a podocyte-derived glycoprotein encoded by SPOCK2 . Circulating levels of testican-2 are associated with less glomerulosclerosis and better kidney prognosis, but its biologic function in the podocyte is unknown. Methods: We studied the protective effect of testican-2 on immortalized cultured human podocytes and in mice treated with adriamycin. We used immunoprecipitation mass spectrometry to identify binding partners of testican-2 and biolayer interferometry to characterize these protein–protein interactions. Using global and podocyte-specific Spock2 knockout mice, we assessed the effect of testican-2 deficiency in models of podocyte injury and also tested whether exogenous testican-2 confers podocyte protection in testican-2–deficient mice. Finally, we analyzed testican-2 expression in human kidney biopsy samples. Results: Testican-2 reduced adriamycin-induced podocyte injury in cultured human podocytes and mice. Vitronectin was a strong binding partner for testican-2, and testican-2 inhibited the interaction between vitronectin and integrin α V β 3, an effector of podocyte injury. Consistent with this, testican-2 administration reduced activation of integrin β 3 in injured podocytes. Furthermore, Spock2 deficiency increased susceptibility to podocyte injury due to adriamycin- and streptozotocin-induced diabetes, as determined by albuminuria, foot process effacement, nephrin expression, and Wilms' tumor 1-positive podocyte number. Importantly, exogenous testican-2 circulated to the kidney, bound to vitronectin, reduced vitronectin-integrin β 3 interaction, and reduced podocyte injury in Spock2 -deficient mice. Finally, glomerular testican-2 expression was reduced in human focal segmental glomerulosclerosis and diabetic kidney disease, but not tubulointerstitial nephropathy. Conclusions: Testican-2 modulated the podocyte's interaction with its extracellular matrix and had a functional role in kidney protection.


  • Inactivating the Innate Immune Receptor CD11b With a First-in-class Monoclonal Antibody Prolongs the Survival of Kidney Allografts in Nonhuman Primates

    by Abbas Dvm Dehnadi, Ivy A. Rosales, Jian-Ping Xiong, Tatsuo Kawai, Hyshem H. Lancia, Gilles Benichou, Robert B. Colvin, A. Benedict Cosimi, M. Amin Arnaout

    Backgournd. Peritransplant ischemia/reperfusion injury (IRI) plays a central pathogenic role in nondelayed or delayed kidney allograft function immediately after transplantation and increases the risk of subsequent rejection. Potential therapies targeting specific cytokines or complement proteins to limit IRI have failed in clinical trials. Monoclonal antibody 107 (mAb107), a “pure” (nonactivating) inhibitor of the archetypal innate immune receptor integrin CD11b, has been shown to extend the survival of IRI nonhuman primate native kidneys in an in situ model. Methods. Here, we administered mAb107 before allograft revascularization to determine its efficacy for extending the survival of ischemia-damaged donor kidneys transplanted into major histocompatibility complex–mismatched nonhuman primate recipients. Results. We observed a significant delay in the onset of rejection and prolongation of allograft survival in mAb107-treated versus control recipients. Early allograft biopsies suggest this is secondary to the selective suppression of infiltrating neutrophils and macrophages. Conclusions. These observations support the hypothesis that inactivating CD11b with mAb107 may provide an effective strategy for prolonging the survival of ischemia-damaged allografts and increasing the successful use of marginal donor organs Export


  • The Integrin Receptors: From Discovery to Structure to Medicines

    by M. Amin Arnaout

    Innate immune cells perform vital tasks in detecting, seeking, and eliminating invading pathogens, thus ensuring host survival. However, loss of function of these cells or their overactive response to tissue injury often causes serious ailments. It is, therefore, crucial to understand at a basic level how these cells function in health and disease. A major step toward this goal came from studies I conducted in the late 1970s investigating the cause of life‐threatening bacterial infections in a pediatric patient. This work led us to trace this disease to the inability of the patient's neutrophils to seek and clear infections due to an inherited deficiency in leukocyte adhesion caused by the loss of a plasma membrane glycoprotein complex now known as CD11/CD18 or β2 integrins. I followed this work by determining the 3‐dimensional structures of integrins. These studies provided the foundation for understanding the unique properties of integrins in mediating bidirectional cell adhesion signaling and enabled a structure‐guided design of compounds to dial down overactive integrins in common disorders, including thromboinflammatory and autoimmune diseases.


  • Open Access

    Platelet integrin αIIbβ3 plays a key role in a venous thrombogenesis mouse model

    by Brian D. Adair, Conroy O. Field, José L. Alonso, Jian-Ping Xiong, Shi-Xian Deng, Hyun Sook Ahn, Eivgeni Mashin, Clary B. Clish, Johannes van Agthoven, Mark Yeager, et al.

    Venous thrombosis (VT) is a common vascular disease associated with reduced survival and a high recurrence rate. VT is initiated by the accumulation of platelets and neutrophils at sites of endothelial cell activation. A role for platelet αIIbβ3 in VT is not established, a task complicated by the increased bleeding risk caused by partial agonists such as tirofiban. Here, we show that m-tirofiban, a modified version of tirofiban, does not agonize αIIbβ3 based on lack of neoepitope expression and the cryo-EM structure of m-tirofiban/full-length αIIbβ3 complex. m-tirofiban abolishes agonist-induced platelet aggregation while preserving clot retraction ex vivo and, unlike tirofiban, it suppresses venous thrombogenesis in a mouse model without increasing bleeding. These findings establish a key role for αIIbβ3 in VT initiation and suggest that m-tirofiban and compounds with a similar structurally-defined mechanism of action merit consideration as potential thromboprophylaxis agents in patients at high risk for VT and hemorrhage.


  • Open Access

    Platelet integrin αIIbβ3 plays a key role in venous thrombogenesis in a mouse model

    by Brian D. Adair, Conroy O. Field, José L. Alonso, Jian-Ping Xiong, Shi-Xian Deng, Hyun Sook Ahn, Eivgeni Mashin, Clary B. Clish, Johannes van Agthoven, Mark Yeager, et al.

    : Venous thrombosis (VT) is a common vascular disease associated with reduced survival and a high recurrence rate. Previous studies have shown that the accumulation of platelets and neutrophils at sites of endothelial cell activation is a primary event in VT, but a role for platelet αIIbβ3 in the initiation of venous thrombosis has not been established. This task has been complicated by the increased bleeding linked to partial agonism of current αIIbβ3 inhibitory drugs such as tirofiban (Aggrastat ® ). Here, we show that m-tirofiban, an engineered version of tirofiban, is not a partial agonist of αIIbβ3. This is based on its cryo-EM structure in complex with human full-length αIIbβ3 and its inability to increase expression of an activation-sensitive epitope on platelet αIIbβ3. m-tirofiban abolished agonist-induced platelet aggregation ex vivo at concentrations that preserved clot retraction and markedly suppressed the accumulation of platelets, neutrophils, and fibrin on thrombin-activated endothelium in real-time using intravital microscopy in a mouse model of venous thrombogenesis. Unlike tirofiban, however, m-tirofiban did not increase bleeding at the thrombosis-inhibitory dose. These findings establish a key role for αIIbβ3 in the initiation of VT, provide a guiding principle for designing potentially safer inhibitors for other integrins, and suggest that pure antagonists of αIIbβ3 like m-tirofiban merit further consideration as potential thromboprophylaxis agents in patients at high-risk for VT and hemorrhage.


  • Open Access

    Cryo-EM structures of full-length integrin αIIbβ3 in native lipids

    by Brian D. Adair, Jian-Ping Xiong, Mark Yeager, M. Amin Arnaout

    Platelet integrin αIIbβ3 is maintained in a bent inactive state (low affinity to physiologic ligand), but can rapidly switch to a ligand-competent (high-affinity) state in response to intracellular signals (“inside-out” activation). Once bound, ligands drive proadhesive “outside-in” signaling. Anti-αIIbβ3 drugs like eptifibatide can engage the inactive integrin directly, inhibiting thrombosis but inadvertently impairing αIIbβ3 hemostatic functions. Bidirectional αIIbβ3 signaling is mediated by reorganization of the associated αIIb and β3 transmembrane α-helices, but the underlying changes remain poorly defined absent the structure of the full-length receptor. We now report the cryo-EM structures of full-length αIIbβ3 in its apo and eptifibatide-bound states in native cell-membrane nanoparticles at near-atomic resolution. The apo form adopts the bent inactive state but with separated transmembrane α-helices, and a fully accessible ligand-binding site that challenges the model that this site is occluded by the plasma membrane. Bound eptifibatide triggers dramatic conformational changes that may account for impaired hemostasis. These results advance our understanding of integrin structure and function and may guide development of safer inhibitors.


    • 1 January 2023
      • Vol. 133, 34-55

    INTEGRINS: A BEDSIDE TO BENCH TO BEDSIDE STORY.

    by M Amin Arnaout

    I provide a narrative of the path I took to discover the membrane receptors that mediate leukocyte adhesion, now known as β2 integrins or CD11/CD18. We followed this discovery with the first determination of the 3-D structures of integrins. The latter advance provided the foundation for understanding the unique features of integrins as divalent cation-dependent signaling receptors and as mechanosensitive conduits between the extracellular matrix and the intracellular cytoskeleton. Our structural studies are now opening new paths for taming overactive integrins in disease while minimizing the collateral damage associated with the faulty pharmacodynamics of current integrin inhibitory drugs.


  • Faculty Opinions recommendation of Structural basis for mismatch surveillance by CRISPR-Cas9.

    by M Amin Arnaout, Johannes van Agthoven

    As DNA editing is being developed for human therapeutics, research has focused on making Crispr-Cas9 editing more reliable to avoid off-target DNA cleavage. In this work, Bravo et al. elucidated the molecular mechanism of off-target cleavage by cryo-EM structure determination of Cas9 in complex with various partially mismatched DNA substrates. Three mismatches (MM) were placed in the guide RNA target strand (gRNA-TS) 18-20, 15-17, and 12-14 bp distal from the protospacer adjacent motif (PAM), and structures were determined following various times of incubations of gRNA-TS MM with Cas-9. The authors identified various degrees of mismatch tolerance by Cas9. Cryo-EM showed two conformations of the gRNA-TS duplex in complex with Cas9: linear and kinked. When mismatches were discriminated by Cas9, the gRNA-TS duplex adopted primarily a linear conformation with the site of mismatch preventing the gRNA-TS from docking the recognition 3 (Rec3) domain of Cas9 (critical in sensing PAM-distal mismatches). In contrast, tolerated mismatches contacted Rec3, and the gRNA-TS transitioned to a kinked conformation, similar to structures of the catalytic Cas9, where cleavage products of TS and non-target strand (NTS) are respectively docked to the HNH and RuvC domains of Cas9. This analysis showed that the linear gRNA-TS conformation is an early intermediate to active Cas9, and activation of Cas9 is blocked if the mismatch prevents the gRNA-TS from docking Rec3. In 12-14 MM, the gRNA-TS conformation converted to kinked as the mismatch is positioned in a blind spot evading match discrimination by Rec3. In the most tolerated 18-20 MM, the unusual duplex conformation at the site of mismatch was stabilized by specific residues in the RuvC domain, which locked the gRNA-TS in a catalytic kinked conformation. A 7-fold mutant of Cas9, SuperFiCas9, in which all contact residues in RuvC were changed to aspartic acids, had a significantly reduced off-target DNA cleavage rate of the 18-20 MM (500-fold slower) while maintaining similar rates of on-target DNA cleavage, a property not achieved in previous designs of modified Cas9. By targeting regions exclusively involved in mismatch tolerance, this study marks a significant technological improvement for future design of high-fidelity Cas variants.

  • Faculty Opinions recommendation of Structural analysis of receptors and actin polarity in platelet protrusions.

    by M Amin Arnaout, Johannes van Agthoven, Brian Adair

    Platelets are small cellular fragments critical for hemostasis. Platelets initiate blood clots by binding soluble fibrinogen with the membrane receptor integrin αIIbβ3. αIIbβ3 is the most abundant receptor on the platelet surface, comprising ~80,000 receptors per cell {1}. In addition to binding extracellular ligands, αIIbβ3 reshapes the cell by transmitting signals to the actin cytoskeleton, resulting in platelet aggregation and clot formation. However, little is known about the actin network structure and integrin αIIbβ3 on living platelets, as most structural information stems from purified integrin ectodomain protein samples. In this study, the authors adhered platelets to fibrinogen-coated EM grids, resulting in cytoskeletal changes generating thin filipodia, covering grid holes in a manner suitable for electron cryotomography (cryo-ET). Reconstruction of the actin filaments yielded a 14Å resolution using a new method coping with low imaging contrast {2}. The structures displayed a non-uniform actin filament network with ~74% ±10 pointing towards the tip of the filopodia protrusion, while the other filaments pointed in the opposite direction. The authors used sub-tomogram averaging of particles selected adjacent to the plasma membrane to investigate the structure of αIIbβ3. Particles on the membrane, the majority of which comprise αIIbβ3, appear flexible and display various conformations. The authors employed extensive 3D classification of the subtomograms to generate a single, well-defined class (containing 5,000 particles out of a total of approximately 74,000 selected), which produced a final 26Å model. The model fits the known bent x-ray structure, albeit slightly more open and adopts an orientation relative to the membrane reminiscent of early models from 2D imaging {3} and resembles a minor species identified in single-particle reconstructions by Xu et al. {4}. Yet, the fact that only the bent conformation was reconstructed may relate to the observation that the imaged particles are on the edge of the platelet membrane visible over the hole, about 60nm above the grid, therefore not in contact with the fibrinogen-coated surface. Thus, the integrin appears to be in the unliganded state, which may explain the absence of αIIbβ3 extension induced by bound fibrinogen shown in a previous study in platelet-derived microparticles {5}. The present integrin structure, however, shows that even in the bent conformation the ligand binding site is accessible to large ligands including fibrinogen and is not blocked by proximity to the plasma membrane, the premise upon which the switchblade model is founded. Overall, this study is an impressive achievement. It offers for the first time a decent model in situ of integrin αIIbβ3 and actin filaments in spreading platelets and provides further insights into the structural basis of integrin-ligand interaction and activation.

  • Faculty Opinions recommendation of X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.

    by M Amin Arnaout, Johannes van Agthoven

    Günther et al. used high-throughput X-ray crystallography screening of drug-repurposing libraries to identify inhibitors of SARS-CoV-2 chymotrypsin-fold main protease (Mpro). Mpro comprises two catalytic domains and one dimerization domain and is essential for cleaving the viral polyprotein 1ab (pp1ab) into the functional polypeptides required for replication and transcriptional activity. The authors' co-crystallized 2381 compounds with the Mpro protein and solved each respective structure. Forty-three compounds, representing 37 distinct compounds, displayed an extra density in the Mpro electron density map, with the binding mode unambiguously determined in 29 of these. Sixteen of the 29 were active site binders; six bound covalently as thioethers to Cys145; one compound bound covalently as a thiohemiacetal to Cys145; one was zinc-coordinated, and eight bound noncovalently. Of the 37 compounds available in quantities for anti-viral testing, 11 showed significant anti-viral activity. Of the 11 compounds analyzed in the secondary screen, one group bound covalently to the Mpro active site Cys145, exemplified by calpeptin that exhibited the highest anti-viral activity and low cytotoxicity in cell-based assays. The remaining compounds bound noncovalently at one of two allosteric sites: pelitinib, an anti-cancer drug with the second-highest anti-viral titer, bound at the C-terminal dimerization domain, and only AT7519, a drug evaluated for cancer, inserted into a groove between the catalytic and the dimerization domains. By identifying new druggable targets in Mpro, this X-ray screening approach provides a useful guide for further structure-based development of drugs targeting SARS-CoV-2 and potentially other coronaviruses